Research
Hormonal
Antiobesity medications require long-term use to prevent weight regain.
Practitioners should emphasize the importance of ongoing medication adherence for effective weight management.
StrongSupportsmedium confidence
Antiobesity medications require long-term use because discontinuation often causes weight regain.
Why this rating
The claim is based on established understanding of obesity management.
Source
Pharmacologic options for the treatment of overweight and obesity
Maria Daniela Hurtado Andrade · Menopause The Journal of The North American Menopause Society · 2025
DOI 10.1097/gme.0000000000002573
reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →